Walter Kraft

TitleProfessor
InstitutionThomas Jefferson University
DepartmentPharmacology & Exp Therapeutic
Address1020 Sansom St.
Philadelphia PA 19107
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    2010Early Career Investigator Award for Distinguished Achievement in Biomedical Research, Jefferson Medical College
    2014Dean's Award for Excellence in Education, Jefferson Medical College

    Collapse Research 
    Collapse research activities and funding
    T32GM008562     (KRAFT, WALTER K)Jul 1, 1995 - Jun 30, 2025
    NIH
    Clinical Pharmacology Training Program
    Role: Co-Principal Investigator

    R21DA018207     (KRAFT, WALTER K.)Sep 1, 2005 - Aug 31, 2009
    NIH
    Buprenorphine Treatment of Neonatal Abstinence Syndrome
    Role: Principal Investigator

    R01DA029076     (KRAFT, WALTER K)Jun 1, 2011 - Apr 30, 2019
    NIH
    A Comparison of Buprenorphine Versus Morphine in the Treatment of the Neonatal Ab
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Smith J, Lafferty M, Boelig RC, Carola D, Adeniyi-Jones S, Kraft WK, Greenspan JS, Aghai ZH. Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? Am J Perinatol. 2020 Dec 15. PMID: 33321531.
      Citations:    
    2. Min KC, Kraft WK, Bondiskey P, Colón-González F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci. 2020 Nov 03. PMID: 33142014.
      Citations:    
    3. Lam E, Schaefer J, Zheng R, Zhan T, Kraft WK. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. Clin Transl Sci. 2020 May 14. PMID: 32407548.
      Citations:    
    4. Ankrom W, Bondiskey P, Li CC, Palcza J, Liu W, Dockendorf MF, Matthews C, Panebianco D, Reynders T, Wagner JA, Jakate A, Mesens S, Kraft WK, Marcantonio EE. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. Clin Transl Sci. 2020 Jan 03. PMID: 31899602.
      Citations:    
    5. Rochani A, Lam E, Tanjuakio J, Hirose H, Kraft WK, Kaushal G. Simultaneous quantitative LC-MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy. J Pharm Biomed Anal. 2020 Jan 30; 178:112947. PMID: 31708269.
      Citations:    
    6. Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann C, Guo Y, Liu R, Iwamoto M. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate co-administration. Antivir Ther. 2019 Aug 21. PMID: 31433304.
      Citations:    
    7. Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol. 2019 Aug; 12(8):781-790. PMID: 31242782.
      Citations:    
    8. Boelig RC, Zuppa AF, Kraft WK, Caritis S. Pharmacokinetics of Vaginal Progesterone in Pregnancy. Am J Obstet Gynecol. 2019 Jun 15. PMID: 31211965.
      Citations:    
    9. Liu T, Lewis TR, Moore JN, Kraft WK, Gauda EB, Sartori D, Moody DE, Gobburu JVS, Ivaturi V. Could Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life? CPT Pharmacometrics Syst Pharmacol. 2019 May 01. PMID: 31044547.
      Citations:    
    10. Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019 Apr 23; 7(1):104. PMID: 31010434.
      Citations:    
    11. McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol. 2019 Apr 16. PMID: 30990905.
      Citations:    
    12. Jones HE, Kraft WK. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. Clin Perinatol. 2019 06; 46(2):349-366. PMID: 31010564.
      Citations:    
    13. Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clin Drug Investig. 2019 Mar 20. PMID: 30895461.
      Citations:    
    14. Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clin Drug Investig. 2019 Feb 27. PMID: 30810914.
      Citations:    
    15. Bashir B, Stickle DF, Chervoneva I, Kraft WK. Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers. Clin Transl Sci. 2018 Jul 03. PMID: 29972633.
      Citations:    
    16. Davis JJ, Price DW, Kraft W, Lane-Fall MB. Incorporation of Quality and Safety Principles in Maintenance of Certification: A Qualitative Analysis of American Board of Medical Specialties Member Boards. Am J Med Qual. 2018 Jul 01; 1062860618785974. PMID: 29973059.
      Citations:    
    17. Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, Ehrlich ME, Kraft WK. The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther. 2018 Mar 08. PMID: 29516490.
      Citations:    
    18. Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018 01 16; 9(1):4. PMID: 29339723.
      Citations:    
    19. Marbach JA, Johnson D, Kloo J, Vira A, Keith S, Kraft WK, Margules N, Whellan D. The Impact of a Transition of Care Program on Acute Myocardial Infarction Readmission Rates. Am J Med Qual. 2018 Jan 01; 1062860618754702. PMID: 29374965.
      Citations:    
    20. Machado P, Stanczak M, Liu JB, Moore JN, Eisenbrey JR, Needleman L, Kraft WK, Forsberg F. Subdermal Ultrasound Contrast Agent Injection for Sentinel Lymph Node Identification: An Analysis of Safety and Contrast Agent Dose in Healthy Volunteers. J Ultrasound Med. 2017 Dec 05. PMID: 29205451.
      Citations:    
    21. Kraft WK. Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther. 2018 Jan; 103(1):112-119. PMID: 29105752.
      Citations:    
    22. Shah AG, Peahota M, Thoma BN, Kraft WK. Medication Complications in Extracorporeal Membrane Oxygenation. Crit Care Clin. 2017 Oct; 33(4):897-920. PMID: 28887935.
      Citations:    
    23. Kraft WK, Adeniyi-Jones SC, Ehrlich ME. Buprenorphine for the Neonatal Abstinence Syndrome. N Engl J Med. 2017 09 07; 377(10):997-998. PMID: 28877016.
      Citations:    
    24. Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017 May 22; 1-12. PMID: 28490202.
      Citations:    
    25. Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Ehrlich ME. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017 06 15; 376(24):2341-2348. PMID: 28468518.
      Citations:    
    26. Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Jun; 10(6):345-354. PMID: 28396341.
      Citations:    
    27. Chalouhi N, Daou B, Okabe T, Starke RM, Dalyai R, Bovenzi CD, Anderson EC, Barros G, Reese A, Jabbour P, Tjoumakaris S, Rosenwasser R, Kraft WK, Rincon F. Beta-blocker therapy and impact on outcome after aneurysmal subarachnoid hemorrhage: a cohort study. J Neurosurg. 2016 Sep; 125(3):730-6. PMID: 26799296.
      Citations:    
    28. Kraft WK, Stover MW, Davis JM. Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. Semin Perinatol. 2016 Apr; 40(3):203-12. PMID: 26791055.
      Citations:    
    29. Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Jan; 22(1):141-8. PMID: 26415558.
      Citations:    
    30. Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy. 2015 Jul; 35(7):670-80. PMID: 26172282.
      Citations:    
    31. Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015 May; 8(3):321-34. PMID: 25916666.
      Citations:    
    32. van den Anker JN, Allegaert K, Kraft WK. Current Therapeutic Research is Now Indexed on PubMed. Curr Ther Res Clin Exp. 2014 Dec; 76:98. PMID: 25389447.
      Citations:    
    33. Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp. 2014 Dec; 76:90-7. PMID: 25379066.
      Citations:    
    34. Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant Medications Altering Gastric pH and Gastric Motility in Healthy Subjects. Antimicrob Agents Chemother. 2014 Jul; 58(7):4020-5. PMID: 24798274.
      Citations:    
    35. Vaid U, Singer E, Marhefka GD, Kraft WK, Baram M. Poor positive predictive value of McConnell's sign on transthoracic echocardiography for the diagnosis of acute pulmonary embolism. Hosp Pract (1995). 2013 Aug; 41(3):23-7. PMID: 23948618.
      Citations:    
    36. Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res. 2013 Sep; 99(3):214-20. PMID: 23747481.
      Citations:    
    37. Okabe T, Kanzaria M, Rincon F, Kraft WK. Cardiovascular Protection to Improve Clinical Outcomes After Subarachnoid Hemorrhage: Is There a Proven role? Neurocrit Care. 2013 Apr; 18(2):271-84. PMID: 23238984.
      Citations:    
    38. Halegoua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ. Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract. Clin Ther. 2012 Dec; 34(12):2279-2285.e1. PMID: 23153661.
      Citations:    
    39. Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. MK-0448, a Specific Kv1.5 Inhibitor: Safety, Pharmacokinetics, and Pharmacodynamic Electrophysiology in Experimental Animal Models and Humans. Circ Arrhythm Electrophysiol. 2012 Dec 1; 5(6):1193-201. PMID: 23060423.
      Citations:    
    40. Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am. 2012 Oct; 59(5):1147-65. PMID: 23036249.
      Citations:    
    41. Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemother Pharmacol. 2012 May; 69(5):1247-53. PMID: 22290273.
      Citations:    
    42. Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012 Jul; 68(7):1049-56. PMID: 22315147.
      Citations:    
    43. Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, Persson A, Huang SP, Hernandez D, Sheaffer AK, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, Demicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera JC, Grasela DM. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44. PMID: 22290978.
      Citations:    
    44. Cavallazzi R, Awe OO, Vasu TS, Hirani A, Vaid U, Leiby BE, Kraft WK, Kane GC. Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis. J Crit Care. 2012 Aug; 27(4):424.e1-6. PMID: 22227088.
      Citations:    
    45. Reitman ML, Dishy V, Moreau A, Denney WS, Liu C, Kraft WK, Mejia AV, Matson MA, Stoch SA, Wagner JA, Lai E. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. J Clin Pharmacol. 2012 Sep; 52(9):1306-16. PMID: 22162541.
      Citations:    
    46. Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK. Formulation of buprenorphine for sublingual use in neonates. J Pediatr Pharmacol Ther. 2011 Oct; 16(4):281-4. PMID: 22768012.
      Citations:    
    47. Henwood PC, Kennedy TM, Thomson L, Galanis T, Tzanis GL, Merli GJ, Kraft WK. The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis. J Thromb Thrombolysis. 2011 Aug; 32(2):209-14. PMID: 21505787.
      Citations:    
    48. Hirani A, Cavallazzi R, Vasu T, Pachinburavan M, Kraft WK, Leiby B, Short W, Desimone J, Squires KE, Weibel S, Kane GC. Prevalence of obstructive lung disease in HIV population: a cross sectional study. Respir Med. 2011 Nov; 105(11):1655-61. PMID: 21703841.
      Citations:    
    49. Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E. The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets. 2011; 22(7):495-503. PMID: 21526889.
      Citations:    
    50. Galanis T, Kraft WK, Merli GJ. Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient. Adv Surg. 2011; 45:361-90. PMID: 21954699.
      Citations:    
    51. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011 Mar; 106(3):574-80. PMID: 20925688.
      Citations:    
    52. Vasu TS, Doghramji K, Cavallazzi R, Grewal R, Hirani A, Leiby B, Markov D, Reiter D, Kraft WK, Witkowski T. Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire. Arch Otolaryngol Head Neck Surg. 2010 Oct; 136(10):1020-4. PMID: 20956751.
      Citations:    
    53. Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010 Oct; 6(10):1277-86. PMID: 20795794.
      Citations:    
    54. Stoch SA, Gargano C, Valentine J, Braun MP, Murphy MG, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Kraft WK, Greenberg HE. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol. 2011 Jun; 67(6):1313-21. PMID: 20734049.
      Citations:    
    55. Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, Wagner JA. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets. 2010; 21(3):191-8. PMID: 20163197.
      Citations:    
    56. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Experimental therapeutics: a paradigm for personalized medicine. Clin Transl Sci. 2009 Dec; 2(6):436-8. PMID: 20443936.
      Citations:    
    57. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Clinical pharmacology: a paradigm for individualized medicine. Biomark Med. 2009 Dec; 3(6):679-84. PMID: 20477706.
      Citations:    
    58. Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009 May; 2(3):295-314. PMID: 21822447.
      Citations:    
    59. Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, Kraft WK. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 2009 May 15; 103(10):1391-5. PMID: 19427434.
      Citations:    
    60. Loboda A, Kraft WK, Fine B, Joseph J, Nebozhyn M, Zhang C, He Y, Yang X, Wright C, Morris M, Chalikonda I, Ferguson M, Emilsson V, Leonardson A, Lamb J, Dai H, Schadt E, Greenberg HE, Lum PY. Diurnal variation of the human adipose transcriptome and the link to metabolic disease. BMC Med Genomics. 2009; 2:7. PMID: 19203388.
      Citations:    
    61. Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9:2. PMID: 19175929.
      Citations:    
    62. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008 Sep; 122(3):e601-7. PMID: 18694901.
      Citations:    
    63. Kraft WK, Waldman SA. Bridging the therapeutic continuum of drug development, regulation and use. Expert Rev Clin Pharmacol. 2008 Jan; 1(1):1-3. PMID: 24410503.
      Citations:    
    64. Larusso J, Waldman SA, Kraft WK. Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. Expert Rev Clin Pharmacol. 2008 Jan; 1(1):27-37. PMID: 24410507.
      Citations:    
    65. Kraft WK, Waldman SA. Expert Review in Clinical Pharmacology. Bridging the Therapeutic Continuum of Drug Development, Regulation and Use. 2008; 1(1):1-3. View Publication.
    66. LaRusso J, Waldman SA, Kraft WK. Expert Review in Clinical Pharmacology. Aprepitant For The Prevention Of Nausea And Vomiting Associated With Chemotherapy And Postoperative Recovery. 2008; 1(1):27-37.
    67. Majumdar AK, Yan KX, Selverian DV, Barlas S, Constanzer M, Dru J, McCrea JB, Ahmed T, Frick GS, Kraft WK, Petty KJ, Greenberg HE. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol. 2007 Jun; 47(6):744-50. PMID: 17463213.
      Citations:    
    68. Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK. The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007 Jun; 47(6):697-703. PMID: 17395893.
      Citations:    
    69. Ghanim AJ, Daskalakis C, Eschelman DJ, Kraft WK. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007 Dec; 24(3):247-54. PMID: 17385008.
      Citations:    
    70. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006 Mar; 46(3):321-7. PMID: 16490808.
      Citations:    
    71. Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Aug; 11(8):609-18. PMID: 16041311.
      Citations:    
    72. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004 Nov; 48(11):4306-14. PMID: 15504857.
      Citations:    
    73. Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol. 2004 Oct; 44(10):1125-31. PMID: 15342613.
      Citations:    
    74. Kraft WK, Waldman SA, Weinberg D, Laine C. Thomas Jefferson University K30 Program Externship: Critical Review of the Medical Literature at The Annals Of Internal Medicine. Clinical Research Perspective. 2004; (1).
    75. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004 Mar; 44(3):305-13. PMID: 14973305.
      Citations:    
    76. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol. 2004 Jan; 44(1):67-72. PMID: 14681343.
      Citations:    
    77. Burke J, Kraft WK, Greenberg HE, Gleave M, Pitari GM, VanBuren S, Wagner JA, Waldman SA. Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. J Clin Pharmacol. 2003 Sep; 43(9):983-9. PMID: 12971030.
      Citations:    
    78. Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003 May; 25(5):1407-19. PMID: 12867217.
      Citations:    
    79. Hastie AT, Kraft WK, Nyce KB, Zangrilli JG, Musani AI, Fish JE, Peters SP. Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge. Am J Respir Crit Care Med. 2002 Jan 15; 165(2):266-72. PMID: 11790666.
      Citations:    
    80. Kraft WK, Waldman SA. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses? Drug Saf. 2001; 24(9):637-43. PMID: 11522118.
      Citations:    
    81. Kraft W, Steinberg M, Delnevo C. How to Help Your Patients Quit Smoking. IM: Internal Medicine. 1999.
    82. Kraft W, Greenberg HE, Waldman SA. Paradoxical hypotension and bradycardia after intravenous arginine vasopressin. J Clin Pharmacol. 1998 Mar; 38(3):283-6. PMID: 9549667.
      Citations:    
    Kraft's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (231)
    Explore
    _
    Co-Authors (56)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _